Effects of combined androgen blockade on bone metabolism and density in men with locally advanced prostate cancer

International Urology and Nephrology

Volumn 34, Issue 1, 2002, Pages 75-79

  Tan, M Özgür ^a   Yilmaz, Cenk ^a   Uygur, M Cemil ^a   Duyur, Burcu ^a   Erol, Demokan ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Bone densitometry; Bone metabolism; Combined androgen blockade; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; BICALUTAMIDE; CALCIUM; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; MAGNESIUM; PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE MINERAL; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FEMUR; HUMAN; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; MALE; ORCHIECTOMY; PATIENT SELECTION; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE COMPLICATION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; SIDE EFFECT; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; BONE AND BONES; BONE DENSITY; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0036945921     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021358912734     Document Type: Article

References (28)

1. Brufsky A, Kantoff PV. Hormonal therapy for prostate cancer. In: Ernsthoff MS, Heaney JA, Peschel RE, eds. Prostate Cancer. Blackwell Science, Inc., USA, 1998: Chapter 11, 160-180.
2. Stepan JJ, Lachman M, Zveir J et al. Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523-527.
3. Finkelstein JS, Klibanski A, Neer RM et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69(4): 776-783.
4. Bichler KH, Petri E, Hub A et al. Investigations on bone metabolism of urological tumors forming metastases. Urol Int 1996; 56: 61-68.
5. Orwoll ES, Stribrska L, Ramsey EE, Keenan EJ. Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int 1991; 49: 182-187.
6. Kasperk CH, Wergedal JE, Farley JR et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576-1578.
7. Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79(3): 545-550.
8. Fogelman I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992; 57: 715-724.
9. Greenspan SL, Oppenheim DS, Klibanski A. Osteoporosis in men with hyperprolectinemic hypogonadism. Ann Intern Med 1986; 104: 777-782.
10. Rigotti NA, Near RM, Jameson L. Osteopenia and bone fractures in a men with anorexia nervosa and hypogonadism. JAMA 1986; 256: 385-388.
11. Smith DAS, Walker M. Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Int 22(Suppl): 225-228.
12. Vermeulen A. Clinical review: Androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221-4.
13. Goldray D, Weisman Y, Jaccard N et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapetyl. J Clin Endocrinol Metab 1993; 76(2): 288-290.
14. Clarke NW, McClure J, George NJR. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993; 24: 286-290.
15. Rico H, Sanchez Chapado MS, Revilla M et al. Total and regional bone mass in metastatic cancer of prostate. Eur Urol 1996; 30: 73-76.
16. Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70(Suppl 1): 254-268.
17. Noordzij NA, Van Steenbrugge GS, Van Der Kwast TH, Schröder PH. Neuroendocrine cells in normal, hyperplastic and neoplastic prostate. Urol Research 1995; 22: 333-341.
18. Tan MÖ, Karaoǧlan Ü, Çelik B et al. Prostate cancer and neuroendocrine differentiation. Int Urol Research 1999; 31(1): 75-82.
19. Aprikian AG, Cordon-Cardo C, Fair WR et al. Neuroendocrine differentiation in metastatic prostatic carcinoma. J Urol 1994; 151: 914-919.
20. Iwamura M, Abrahamsson PA, Foss KA, Cockett ATK. Autocrine regulation of prostate cancer cell growth by parathyroid hormone related protein. J Urol 1993; 149(Suppl 4): 482A.
21. Wu G, Gershagen S, Iwamura M et al. Detection of parathyroid hormone related protein m-RNA in neuroendocrine cells of prostate gland by in situ hybridization with exon specific probes. J Urol 1994; 151(5, Suppl): 296A.
22. Davis NS, Di Sant'Agnese PA. Calcitonin levels and neuroendocrine cells in human prostate cancer. J Urol 1990: 143(Suppl): 337A.
23. Rico H, Uson A, Hernandez ER et al. Hyper-parathyroidism in metastases of prostatic carcinoma: A biochemical, hormonal and histomorphometric study. Eur Urol 1990; 17: 35-39.
24. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to cyclic etidronate therapy. Cancer 1998; 83(8): 1561-1568.
25. Ernst SD, MacDonald NR, Paterson AHG et al. A double-blind crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7: 4-11.
26. Daniell HW, Dunn SR, Ferguson DW et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
27. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-1222.
28. Wei JT, Gross M, Jaffe CA et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54(4): 607-611.